NASDAQ$ALXO

ALX Oncology Holdings Inc · Q3 2019 earnings

Q3 2019 earnings · · Investor relations

Headline financials

Total Revenue

$1.26M

No prior period
EPS (adj)

-$0.14

No prior period
Net Income

-$3.04M

No prior period
Operating Income

-$3.03M

No prior period
Gross Profit

$114K

No prior period
R&D Expense

$2.21M

No prior period

Revenue & EPS history

ALX Oncology · Revenue · Quarterly

$1.26M

Q3 2019
Beat estimate in 1 of 2 quarters(50%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports

Historical avg

+1.0%

Avg return

Earnings day

+2.2%

Avg return

5 days after

+2.7%

Avg return

30 days after

59%

13 / 22 earnings

Positive

+26.0%

Q4 2024

Best reaction

-21.9%

Q4 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-10.2%-6.8%-13.2%
Q3 2025+15.5%+8.5%+20.3%
Q2 2025+7.4%+57.9%+72.4%
Q1 2025-8.2%-0.2%+25.9%
Q4 2024+26.0%-6.4%-50.4%
Q3 2024-5.2%-12.4%+5.9%
Q1 2024-2.4%-8.7%-45.8%
Q4 2023+3.0%-16.2%-17.2%
Q3 2023+13.2%+21.8%+70.5%
Q2 2023+1.4%-2.6%-1.4%
Q1 2023+0.6%-7.0%+23.3%
Q4 2022-13.6%-15.9%-28.7%
Q3 2022-1.8%+1.1%-14.2%
Q2 2022+2.6%+26.6%+5.6%
Q1 2022-6.8%-8.1%-24.1%
Q4 2021+7.7%-1.3%+2.7%
Q3 2021+8.8%+6.3%-26.4%
Q2 2021+0.6%+2.1%+16.6%
Q1 2021-1.1%-1.6%+7.3%
Q4 2020-21.9%-19.4%-24.8%
Q3 2020+4.2%+34.6%+65.1%
Q2 2020+2.0%-3.8%-10.0%
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro